NASDAQ
OSUR

OraSure Technologies Inc

Medical Instruments & Supplies
Healthcare

Prices are adjusted according to historical splits.

OraSure Technologies Inc Stock Price

Vitals

Today's Low:
$5.77
Today's High:
$6.08
Open Price:
$6.01
52W Low:
$3.45
52W High:
$7.82
Prev. Close:
$6.02
Volume:
574068

Company Statistics

Market Cap.:
$441.96 million
Book Value:
5.369
Revenue TTM:
$479.94 million
Operating Margin TTM:
8.39%
Gross Profit TTM:
$147.64 million
Profit Margin:
8.96%
Return on Assets TTM:
5.7%
Return on Equity TTM:
11.65%

Company Profile

OraSure Technologies Inc had its IPO on 1986-11-12 under the ticker symbol OSUR.

The company operates in the Healthcare sector and Medical Instruments & Supplies industry. OraSure Technologies Inc has a staff strength of 840 employees.

Stock update

Shares of OraSure Technologies Inc opened at $6.01 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.77 - $6.08, and closed at $5.81.

This is a -3.49% slip from the previous day's closing price.

A total volume of 574,068 shares were traded at the close of the day’s session.

In the last one week, shares of OraSure Technologies Inc have slipped by -9.78%.

OraSure Technologies Inc's Key Ratios

OraSure Technologies Inc has a market cap of $441.96 million, indicating a price to book ratio of 1.1173 and a price to sales ratio of 1.1226.

In the last 12-months OraSure Technologies Inc’s revenue was $479.94 million with a gross profit of $147.64 million and an EBITDA of $62.10 million. The EBITDA ratio measures OraSure Technologies Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, OraSure Technologies Inc’s operating margin was 8.39% while its return on assets stood at 5.7% with a return of equity of 11.65%.

In Q2, OraSure Technologies Inc’s quarterly earnings growth was a negative -41.9% while revenue growth was a positive 6.5%.

OraSure Technologies Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
10.5614
PEG
2.3

Its diluted EPS in the last 12-months stands at $0.57 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 2.3. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into OraSure Technologies Inc’s profitability.

OraSure Technologies Inc stock is trading at a EV to sales ratio of 0.9116 and a EV to EBITDA ratio of -22.1405. Its price to sales ratio in the trailing 12-months stood at 1.1226.

OraSure Technologies Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$453.59 million
Total Liabilities
$46.42 million
Operating Cash Flow
$37.16 million
Capital Expenditure
$2.97 million
Dividend Payout Ratio
0%

OraSure Technologies Inc ended 2024 with $453.59 million in total assets and $0 in total liabilities. Its intangible assets were valued at $453.59 million while shareholder equity stood at $394.14 million.

OraSure Technologies Inc ended 2024 with $0 in deferred long-term liabilities, $46.42 million in other current liabilities, in common stock, $-115163000.00 in retained earnings and $35.61 million in goodwill. Its cash balance stood at $185.94 million and cash and short-term investments were $185.94 million. The company’s total short-term debt was $2,975,000 while long-term debt stood at $0.

OraSure Technologies Inc’s total current assets stands at $341.57 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $52.75 million compared to accounts payable of $17.75 million and inventory worth $73.28 million.

In 2024, OraSure Technologies Inc's operating cash flow was $37.16 million while its capital expenditure stood at $2.97 million.

Comparatively, OraSure Technologies Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$5.81
52-Week High
$7.82
52-Week Low
$3.45
Analyst Target Price
$6.94

OraSure Technologies Inc stock is currently trading at $5.81 per share. It touched a 52-week high of $7.82 and a 52-week low of $7.82. Analysts tracking the stock have a 12-month average target price of $6.94.

Its 50-day moving average was $5.59 and 200-day moving average was $5.65 The short ratio stood at 3.17 indicating a short percent outstanding of 0%.

Around 422.1% of the company’s stock are held by insiders while 8843.2% are held by institutions.

Frequently Asked Questions About OraSure Technologies Inc

The stock symbol (also called stock or share ticker) of OraSure Technologies Inc is OSUR

The IPO of OraSure Technologies Inc took place on 1986-11-12

Similar Industry Stocks (Medical Instruments & Supplies)

Last Price
Chg
Chg%
$42.46
0.77
+1.85%
$0.14
0
0%
$30.11
-1.41
-4.47%
$4.45
0
0%
$23.33
0.18
+0.78%
$11.49
0
0%
$37.8
-0.79
-2.05%
$1.12
-0.08
-6.51%
$0.86
-0
-0.23%
$114.5
-7.6
-6.22%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company’s diagnostic products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene ” GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene ” GUT DNA and RNA collection devices; and OMNIgene”GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

Address

220 East First Street, Bethlehem, PA, United States, 18015